Peripheral Hemodynamic and Humoral Effects of Oral Zofenopril Calcium (SQ. 26,991) in Patients with Congestive Heart Failure

Publisher Website
Google Scholar
Abstract
In 14 patients with congestive heart failure (CHF) of various grade (NYHA class 2–4) the effects of zofenopril calcium (SQ 26,991) on blood pressure and forearm circulation were studied by venous occlusion pletismography. Changes in plasma renin activity (PRA), aldosterone, Atrial natriuretic factor (ANF) and arginine‐vasopressin (AVP) were also measured. Two hours after oral administration of 7.5 mg of zofenopril we observed a decrease in blood pressure, heart rate, and forearm vascular resistance along with an increase in venous distensibility. Zofenopril also decreased ANP levels in a manner directly related to peripheral venodilatation (r = .64; P < .05) and modified arginine‐vasopressin (AVP) proportionally to the fall in blood pressure observed in response to drug administration (%SBP/%AVP: r = .64, P < .05; % DBP/%AVP: r = .67, P < .05). Hemodynamic and humoral responses to zofenopril occurred without any significant unwanted adverse reaction, even in patients with greater pressor reduction. We conclude that oral acute zofenopril administration, in patients with congestive heart failure, causes an arterial and venous forearm vasodilatation which is probably involved in the acute changes in plasma levels of ANF and AVP observed after drug administration.